Event
BIOE Seminar Series: Lola Eniola-Adefeso (University of Michigan)
Friday, September 4, 2020
9:00 a.m.-10:00 a.m.
Virtual
Gregg Duncan
gaduncan@umd.edu
The Fall 2020 seminars will be held virtually on Fridays from 9:00 a.m. – 9:50 a.m., unless otherwise noted. All BIOE faculty, students, staff, postdocs, and affiliates as well as additional subscribers to our weekly seminars emails will receive Zoom event information the week of each seminar.
If you do not yet receive our weekly seminars email and would like to subscribe to the listserv, or if you would like to attend this particular seminar, please email Emily Rosenthal.
Dr. Lola Eniola-Adefeso
Professor, Chemical Engineering
University of Michigan
Understanding Cellular-Particle Interactions in Blood: Implications for Disease Pathology and Treatment
Localized delivery of therapeutics offers the possibility of increased drug effectiveness while minimizing side effects often associated with systemic drug administration. Factors that influence the likelihood of targeted particle therapeutics to reach the vascular wall are the ability to identify: 1) a disease-specific target, 2) the appropriate drug carrier type and geometry for efficient interaction with the vascular wall, and 3) a drug-carrier combination that allows for the desired release of the targeted therapeutics. Existing literature has focused on identifying target epitopes and the degradation/drug release characteristics of a wide range of drug-carrier formulations. Our work focuses on probing the role of particle geometry, material chemistry, and blood rheology/dynamics on the ability of vascular-targeted drug carriers to interact with the blood vessel wall - an important consideration that will control the effectiveness of drug targeting regardless of the targeted disease or delivered therapeutically. This presentation will highlight the carrier-blood cell interactions that affect drug carrier binding to the vascular wall and alter critical neutrophil functions in disease. The talk will present the optimal drug carrier geometry for active and passive use of VTC in the treatment of many inflammatory diseases.
